{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:51:34Z","timestamp":1773028294075,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p><jats:bold>Abstract: Background: <\/jats:bold> Budesonide, which is a dual substrate of P\u2010glycoprotein, the product of the multidrug resistance 1 (MDR1) gene, and cytochrome P450 3A (CYP3A) has been proposed for treatment of early primary biliary cirrhosis (PBC). Recently, MDR1 gene polymorphisms have been discussed as a potential cause of glucocorticoid resistance. We tested the hypothesis that MDR1 gene polymorphisms affect absorption of oral budesonide.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> In 21 patients with histologically proven early\u2010stage (I\/II) PBC and nine healthy subjects, we evaluated the impact of MDR1 single nucleotide polymorphisms (2677G&gt;T,A and 3435C&gt;T) on disposition of a single oral dose of 3\u2003mg budesonide. CYP3A5 gene polymorphisms (6986A&gt;G) were analyzed in parallel.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> In MDR1 2677 GG and 3435 CC genotypes, absorption and elimination of budesonide were not significantly different from those in corresponding homozygous variants. Peak plasma levels and areas under the plasma concentration time curves (AUC) of budesonide were not lower in MDR1 3435 CC with putatively high intestinal expression of P\u2010glycoprotein than in MDR1 3435 TT. Interestingly, in two CYP3A5<jats:sup>*<\/jats:sup>1\/<jats:sup>*<\/jats:sup>3 carriers with high enzyme activity, lower AUC was noted than in 28 CYP3A5<jats:sup>*<\/jats:sup>3\/<jats:sup>*<\/jats:sup>3 carriers with a deficient enzyme.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> Common MDR1 gene polymorphisms do not affect disposition of budesonide in early PBC.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01222.x","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T15:57:57Z","timestamp":1138204677000},"page":"285-290","source":"Crossref","is-referenced-by-count":7,"title":["Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis"],"prefix":"10.1111","volume":"26","author":[{"given":"Karin","family":"Dilger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Gr\u00fcnhage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Hohenester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Sauerbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140233"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.21.7735"},{"key":"e_1_2_6_4_2","first-page":"159","article-title":"The gut as a barrier to drug absorption","volume":"40","author":"Zhang Y","year":"2001","journal-title":"combined role of cytochrome P450 3A and P-glycoprotein"},{"key":"e_1_2_6_5_2","first-page":"13","article-title":"Polymorphisms in human MDR1 (P\u2010glycoprotein)","volume":"75","author":"Marzolini C","year":"2004","journal-title":"recent advances and clinical relevance"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.9.3004"},{"key":"e_1_2_6_7_2","first-page":"918","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis","volume":"117","author":"Leuschner M","year":"1999","journal-title":"results of a prospective double-blind trial"},{"key":"e_1_2_6_8_2","first-page":"747","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis","volume":"41","author":"Rautiainen H","year":"2005","journal-title":"a three-year randomized trial"},{"key":"e_1_2_6_9_2","first-page":"42","volume-title":"Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy","author":"M\u00f6llmann H W","year":"1996"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311303"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00012"},{"key":"e_1_2_6_12_2","first-page":"137","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"Jonsson G","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-100101904"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/phgs.5.3.243.29833"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1780339"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70210-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(02)00426-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50266"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20568"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.233"},{"key":"e_1_2_6_21_2","volume-title":"TopFit Version 2.0: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC","author":"Heinzel G","year":"1993"},{"key":"e_1_2_6_22_2","first-page":"633","article-title":"Pharmacokinetic characteristics for extent of absorption and clearance in drug\/drug interaction studies","volume":"32","author":"Schall R","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.114164"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000090753.99170.89"},{"key":"e_1_2_6_25_2","first-page":"3473","article-title":"Functional polymorphisms of the human multidrug resistance gene","volume":"97","author":"Hoffmeyer S","year":"2000","journal-title":"multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200112000-00005"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.3.360"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2004.00223.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119784"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050776"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01238.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020526"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.127739"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443090-00001"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/86882"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.1.162"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200403000-00002"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00168-1"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000137789.58694.B4"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.013"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01222.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01222.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:14:29Z","timestamp":1697102069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01222.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01222.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01222.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,9]]}}}